Speaker illustration

Professor Ting-Hsing Chao

National Cheng Kung University Hospital, Tainan (Taiwan)

Cilostazol improves hyperglycemia-induced impaired vasculo-angiogenesis through stimulating adiponectin/adiponectin receptor 1/Sirtuin 1 signaling pathway

Event: ESC Congress 2020

Topic: Antiplatelet Drugs

Session: Pharmacology and Pharmacotherapy ePosters


A randomized controlled trial evaluating outcome impact of cilostazol in patients with coronary artery disease and at a high risk of cardiovascular disease

Event: ESC Congress 2019

Topic: Antiplatelet Drugs

Session: Evolving developments in anti-platelet therapy


The associations between the effect of cilostazol on the proprotein convertase subtilisin/kexin type 9 concentrations and circulating endothelial progenitor cells and vasculo-angiogenesis factors

Event: ESC Congress 2018

Topic: Pharmacotherapy

Session: Peripheral vascular and cerebrovascular disease: pathophysiology


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb